4basebio (LON:4BB – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported GBX (1.09) earnings per share for the quarter, Digital Look Earnings reports. The company had revenue of GBX 169 million for the quarter.
4basebio Trading Up 6.9%
Shares of 4BB traded up GBX 33 during mid-day trading on Thursday, reaching GBX 513. 3,083 shares of the company’s stock traded hands, compared to its average volume of 1,616. The stock has a market cap of £79.44 million, a P/E ratio of -5.18 and a beta of 1.09. The stock’s 50-day moving average is GBX 496.49 and its two-hundred day moving average is GBX 581.33. 4basebio has a 12 month low of GBX 420 and a 12 month high of GBX 1,150. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.
About 4basebio
Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.
Featured Stories
- Five stocks we like better than 4basebio
- Target Shows Strengths, But Analysts Want to See More
- NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating
- Corpay’s Quiet Strength Is Winning Wall Street
- Investors Abandoned These 3 AI Stocks Too Early, Says Jeff Clark
Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.
